Effect of Rosiglitazone on the Differential Expression of Diabetes-associated Proteins in Pancreatic Islets of C57Bl/6 lep/lep Mice*

Jean-Charles Sanchez‡§, Véronique Converset‡, Anna Nolan¶, Gerhard Schmid‡, Steven Wang¶, Manfred Heller‡, Matthew V. Sennitt¶, Denis F. Hochstrasser‡, and Michael A. Cawthorne¶

The insulin sensitizer drug, rosiglitazone, has been shown to have a protective effect on pancreatic islet structure and function in animal models of type 2 diabetes. The identification of new molecular targets associated both with islet cell dysfunction and protection is a crucial research goal. In the present study, a proteomics approach was used to identify such targets. Obese C57Bl/6J lep/lep mice and lean littermates were given the insulin sensitizer drug BRL49653, rosiglitazone. It normalized the impaired glucose tolerance in lep/lep mice but had no significant effect on glucose tolerance in the lean mice. Pancreatic islet polypeptides were arrayed by a two-dimensional gel electrophoresis system that separated more than 2500 individual spots. Three overexpressed and six underexpressed proteins were significant (p < 0.05) between lep/lep and lean mice, and four were modulated significantly (p < 0.05) by the rosiglitazone treatment of the obese mice. The identity of these differentially expressed proteins was made using mass spectrometric analysis and provided evidence that differential expression of actin-binding proteins may be an important aspect of defective islet function. Rosiglitazone increased carboxypeptidase B expression in both lep/lep and normal mice suggesting that this might be an independent effect of rosiglitazone that contributes to improved insulin processing. Molecular & Cellular Proteomics 1: 509–516, 2002.

Type 2 diabetes is a complex metabolic disease involving defects in both insulin secretion and insulin action and is influenced by a range of genetic and environmental factors (1). As in other polygenic diseases, including cancers and cardiovascular diseases, advances in molecular genetic approaches have made it possible to start to identify susceptibility genes of type 2 diabetes, but so far the search for candidate genes has been largely negative (2) probably as a result of redundancy and compensatory mechanisms (3). Linear genetic strategies are thus not sufficient to predict specific phenotypes, and more global approaches that combine genomic and proteomic investigation are required.

Whether insulin resistance or insulin secretion defects are primary in the development of type 2 diabetes has been a highly debated topic, and there is no consensus. However, it is clear that overt type 2 diabetes only occurs when the insulin output from the pancreatic islet fails to match the insulin requirement as a result of the insulin resistance (4).

Current therapies targeted to the pancreatic islet are agents such as sulfonylureas that increase meal-induced insulin secretion. However, it is clear that although these agents can be effective in the short term they can also accelerate the progression of the diabetic state (5). There is a growing opinion that new agents are required that increase the pancreatic islet cell mass and/or enhance the production of insulin by the islet cell (6). Recently, insulin sensitizer drugs, such as BRL49653 (rosiglitazone), have become available. These agents increase insulin sensitivity of adipose tissue, skeletal muscle, and liver (7) and reduce the insulin requirement. BRL49653 has also been shown to prevent or alleviate islet hyperplasia in Zucker fa/fa rats (8), and human studies provide evidence of islet cell protection (9). Animal studies have also shown that islet cell mass might affect significantly the susceptibility to develop diabetes. Thus, C57Bl/6 mice have twice the islet cell mass of C57Bl/Ks mice (10), and the latter mice are significantly more susceptible to diabetes induced by chemical damage (11) or as a result of the acquisition of the obesity or obesity receptor gene mutations lep or lepR, previously known as ob and db (12).

In the present study, we have used two separate phenotypic paradigms to undertake a systematic identification of proteins associated with anatomical and functional abnormalities of pancreatic islets. First we have used C56Bl/6J lep/lep mice and lean littermates that have been treated with the insulin sensitizer BRL49653. Because this agent normalizes glucose tolerance and insulin sensitivity in the lep/lep mice but has little effect in the littermates (7), it follows that islet proteins that are expressed differentially between lep/lep and lean C57Bl/6J mice and whose expression is modulated by...
BRL49653 only in the lep/lep mice are disease-associated proteins. Second, we have examined the differential expression of islet proteins in C57B/B6 and C57B/Ks mice to identify proteins potentially associated with low islet cell mass.

**EXPERIMENTAL PROCEDURES**

Reagents and Apparatus—All reagents and apparatus used have been described in detail elsewhere (13). Mice were obtained from Jackson Laboratories, Bar Harbor, ME.

Mice Treatment—All mice used in this study were 8-week-old females, and they were housed on a 12-h light cycle (light turned on at 08:00) at 21 °C and given food (rat and mouse standard diet; B & K Universal, Hull, United Kingdom) and water ad libitum. Each group of mice had its food consumption measured daily. Lean (n = 4) and obese (n = 4) control C57B/B6 lep/lep mice were given powdered diet. Lean (n = 4) and obese (n = 4) treated C57B/B6 lep/lep mice were given BRL49653, rosiglitazone (7) (Dextra Laboratories, Readings Berks, United Kingdom) by dietary admixture at the rate of 10 mg/kg diet for 7 days. After an overnight fast, mice were given glucose (3.0 g/kg body weight, per os). Blood from the tail (20 μl) was taken every 30 min (−30 min to +180 min after glucose was given). Blood glucose concentrations were measured as described previously (14). All animal studies were approved by the local ethical review committee and were carried out in accordance with United Kingdom government regulations and NIH guidelines on the care and welfare of laboratory animals.

Pancreatic Islet Preparations and Solubilization—Mice were anesthetized with 50% hyperonavol and 50% hypononavol and then killed with carbon dioxide gas. The pancreas was removed, and pancreatic islets were isolated by collagenase digestion at 37 °C using a physiological saline solution supplemented with 1 mM CaCl2, 4 mM glucose and equilibrated with CO2:O2 (5%:95%), pH 7.4 (15). Islets were hand-picked using a binocular microscope, washed, microdissected to remove residual acinar material, and finally snap-frozen in liquid nitrogen and stored at −80 °C until analysis. 200 (analytical gels) or 1,000 (preparative gels) islets were mixed with 60 μl of a solution containing urea (8 M), CHAPS (4% w/v), Tris (40 mM), dithiothreitol (65 mM) carbon dioxide gas. The pancreas was removed, and pancreatic islets were placed in a 50 ml Falcon tube. To each tube 60 ml containing urea (8 M), CHAPS (4% w/v), Tris (40 mM), dithiothreitol (65 mM), CO2:O2 (5%:95%), pH 7.4 was added. The tubes were vortexed, incubated on a 6°C water bath, homogenized with a Polytron for 30 s, and centrifuged at 1,000 × g for 5 min. The supernatant was loaded in each well of a 96-well matrix-assisted laser desorption ionization target plate. The samples were air-dried. Then 2 μl of a solution containing 4 mg/ml of α-cyano-4-hydroxycinnamic acid, 50% acetonitrile, and 0.1% trifluoroacetic acid was added on each well and air-dried. The peptide mixtures were analyzed by a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (Applied Biosciences Voyager Elite MALDI-TOF-MS) with a nitrogen laser (337 nm) and operated in reflectron-delayed extraction mode. Protein identification was carried out using Smartident (www.expasy.ch/sprot/Smartident.html). It is a tool that allows the identification of proteins using pI, molecular weight, and peptide mass fingerprinting data. Experimentally measured, user-specified peptide masses were compared with the theoretical peptides calculated for all proteins in the SWISS-PROT/TREMBL databases.

Protein Identification by Peptide Fragmentation—4 μl of the supernatant was desalted by a liquid reversed-phase chromatography system with C18 (75-μm diameter and 10-cm-long) microcolumns. Peptides were applied by nanoflow (in-house nanospray) sample introduction to a tandem mass spectrometer that consists of two quadrupoles and an orthogonal time of flight tube (Q-TOF-MS) from Micromass (Manchester, United Kingdom). Fragment ion spectra were interpreted with the SEQUEST database search (ThermoFinnigan, San Jose, CA) and compared with theoretical ones from different databases such as SWISS-PROT, TREMBL, and/or expressed sequence tag databases.

**RESULTS**

Oral Glucose Tolerance Test—The obese C56Bl/6J lep/lep strain shows hyperphagia, insulin resistance, glucose intolerance, and fasting hyperglycemia (23) relative to its lean littersmates. To check the efficacy of rosiglitazone on blood glucose concentration, an oral glucose tolerance test was performed on the four groups of mice (i.e. lean control, obese (lep/lep) control, lean treated, and obese (lep/lep) treated). Fig. 1 shows that the area under the blood glucose concentration curve of the obese control group is much greater than the lean control. Treatment of the obese group with rosiglitazone normalized the glucose tolerance, whereas treatment of the lean group had no further effect. These results validated that rosiglitazone improves the glycemc of the lep/lep group and does not provoke hypoglycemia in the lean littermates.

2-DE Gel Separation and Identification of Proteins—Mouse islets were arrayed on the 2-DE gel system, and proteins were stained. Differential analysis (>200%) and Student's t test (p < 0.05) using the relative volume of each spot (>0.04%) allowed the detection of significantly over- and underexpressed polypeptides with a minimum ratio of two.

Protein Identification by Mass Spectrometry—The identity of the differentially expressed proteins was made using mass spectrometric analysis including peptide mass fingerprinting analysis and then peptide fragmentation for their validation. Coomassie Blue 2-DE spots were destained with 100 μl of 30% acetonitrile in 50 mM ammonium bicarbonate at 37 °C for 45 min. The supernatant was discarded, and the gel spots were dried in a SpeedVac for 30 min. The gel spots were rehydrated with 25 μl of a solution containing 0.2 μg of porcine trypsin and 50 mM ammonium bicarbonate for 2 h at 35 °C. Then the gel spots and supernatant were dried in a SpeedVac for 30 min, rehydrated with 20 μl of H2O for 30 min at 35 °C, and dried again for 30 min. 5 μl of a solution containing 50% acetonitrile and 0.1% trifluoroacetic acid was added to the spots and sonicated for 10 min.

Protein Identification by Peptide Mass Fingerprinting—1 μl of the supernatant was loaded in each well of a 96-well matrix-assisted laser desorption ionization target plate. The samples were air-dried. Then 2 μl of a solution containing 4 mg/ml of α-cyano-4-hydroxycinnamic acid, 50% acetonitrile, and 0.1% trifluoroacetic acid was added on each well and air-dried. The peptide mixtures were analyzed by a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (Applied Biosciences Voyager Elite MALDI-TOF-MS) with a nitrogen laser (337 nm) and operated in reflectron-delayed extraction mode. Protein identification was carried out using Smartident (www.expasy.ch/sprot/Smartident.html). It is a tool that allows the identification of proteins using pI, molecular weight, and peptide mass fingerprinting data. Experimentally measured, user-specified peptide masses were compared with the theoretical peptides calculated for all proteins in the SWISS-PROT/TREMBL databases.

Protein Identification by Peptide Fragmentation—4 μl of the supernatant was desalted by a liquid reversed-phase chromatography system with C18 (75-μm diameter and 10-cm-long) microcolumns. Peptides were applied by nanoflow (in-house nanospray) sample introduction to a tandem mass spectrometer that consists of two quadrupoles and an orthogonal time of flight tube (Q-TOF-MS) from Micromass (Manchester, United Kingdom). Fragment ion spectra were interpreted with the SEQUEST database search (ThermoFinnigan, San Jose, CA) and compared with theoretical ones from different databases such as SWISS-PROT, TREMBL, and/or expressed sequence tag databases.

**RESULTS**

Oral Glucose Tolerance Test—The obese C56Bl/6J lep/lep strain shows hyperphagia, insulin resistance, glucose intolerance, and fasting hyperglycemia (23) relative to its lean littersmates. To check the efficacy of rosiglitazone on blood glucose concentration, an oral glucose tolerance test was performed on the four groups of mice (i.e. lean control, obese (lep/lep) control, lean treated, and obese (lep/lep) treated). Fig. 1 shows that the area under the blood glucose concentration curve of the obese control group is much greater than the lean control. Treatment of the obese group with rosiglitazone normalized the glucose tolerance, whereas treatment of the lean group had no further effect. These results validated that rosiglitazone improves the glycemc of the lep/lep group and does not provoke hypoglycemia in the lean littermates.

2-DE Gel Separation and Identification of Proteins—Mouse islets were arrayed on the 2-DE gel system, and proteins were
Diabetes-associated Differential Protein Expression

Fig. 1. Oral glucose tolerance test. Lean (n = 4) and obese (n = 4) control C57Bl/6J lep/lep mice were given powdered standard diet. Lean (n = 4) and obese (n = 4) treated C57Bl/6J lep/lep mice were given BRL49653, rosiglitazone (19), by dietary admixture at the rate of 10 mg/kg diet for 7 days. After an overnight fast, mice were given glucose (3.0 g/kg body weight, per os), and blood (20 µl) was taken from the tail every 30 min (−30 min to +180 min after glucose was given). Blood glucose concentrations (mmol/liter) were measured by the glucose oxidase method. Results are given as mean ± S.E. Significant differences between glucose concentrations in lep/lep mice given rosiglitazone relative to lep/lep controls are indicated by *, p < 0.05; **, p < 0.01; and ***, p < 0.001.

identified by mass spectrometric analysis. From the 2528 detected spots corresponding approximately to 1500 proteins and representing only 10% of the whole islet proteome, 63 have been identified that correspond to 44 protein entries. The data have been established in the mouse SWISS-2DPAge database (24). The database can be found on the ExPASy server (www.expasy.ch/cgi-bin/map2/def?ISLETS_MOUSE). Fig. 2 shows the 2-DE gel electrophoresis image of mouse islets of Langerhans with differentially expressed protein locations marked.

Changes of Protein Expression between lep/lep Mouse Islets and Lean Littermates—Image analysis allowed the detection and identification (Fig. 3) of six underexpressed (4-fold reduction in tropomyosin isoform 1, 10-fold reduction of dihydropteridine reductase and dihydropteridine reductase fragment, 4-fold reduction in glutathione S-transferase P1, 4-fold reduction of β-granin, and 3-fold reduction of calgranulin B) and three overexpressed polypeptides (3-fold increase in adipocyte fatty acid-binding protein and 4-fold increase of profilin and profilin fragment) in obese controls relative to lean mice (p < 0.05).

Changes of Protein Expression Induced by Treatment with BRL49653—Of the nine polypeptides differentially expressed between lep/lep mouse islets and lean littermates, four were modulated significantly (p < 0.05) after treatment of the lep/lep mice, but not in the lean littermates, with BRL49653. These (tropomyosin isoform 1, adipocytes fatty acid-binding protein, profilin, and profilin fragment) had their expression level altered toward the level in the lean littermates (Fig. 4). In addition, BRL49653 increased carboxypeptidase B precursor protein expression in both lep/lep and normal mice (Fig. 5).

Differential Polypeptide Expression between C57Bl/6 and C57Bl/Ks Mice—The yield of islets from lean C57Bl/Ks mice was on average only 50% of the yield from C57Bl/6 mice, and the Ks islets were smaller, in agreement with the studies of Swenne and Andersson (10). Of the 31 polypeptides found to be differentially expressed between these two genotypes (data not shown), two of the proteins (tropomyosin and profilin) had similar levels of expression in the C57Bl/Ks mice to that in the C57Bl/6 lep/lep mice (Fig. 6).

DISCUSSION

The obese C57Bl/6J lep/lep mouse strain shows obesity, hyperphagia, insulin resistance, glucose intolerance, and mild fasting hyperglycemia (23). Hyperplasia and hypertrophy of β-cell mass are also present (25). The obese phenotype results from a nonsense mutation in codon 105 of the ob gene located in chromosome 6 (26). The ob gene is expressed mainly in white adipose tissue, and its mutation leads to a failure to secrete the gene product into the circulation. The gene product, leptin (“leptos” in Greek means thin), acts on the hypothalamus to regulate appetite (27). However, leptin receptors (product of the db gene) are also present in a variety.
of tissues (28) including pancreatic islet cells, and leptin affects insulin secretion (29). The hyperplasia and hypertrophy of the β-cell mass in C57Bl/6J lep/lep mice is not solely due to the lep mutation, because when the mutation is expressed on the C57Bl/Ks background, islet cells become damaged, and the mice develop frank diabetes (12). Other studies have shown fundamental differences in islet cell mass between wild-type C57Bl/6 and C57Bl/Ks mice (10).

Recently it has been shown that, in addition to its primary effect on insulin sensitivity, rosiglitazone increases the insulin content of the pancreas in diabetic rats, as well as the number and total mass of islet cells (8, 9). Whether this is a direct effect of rosiglitazone through activation of a peroxisome proliferator-activated receptor γ-mediated pathway in islets or an indirect result of normalizing the glycemia is not known, but the molecular changes that are associated with this islet cell remodeling are potentially important to the long term efficacy of rosiglitazone. In the current study, nine significant (p < 0.05) differentially expressed polypeptides were detected between lep/lep and control mice, and four of these were modulated by rosiglitazone treatment only in lep/lep mice.

Of the differentially expressed proteins not modulated by rosiglitazone, dihydropteridine reductase (and a fragment) were reduced 10-fold in islets from lep/lep mice. Dihydropteridine reductase converts dihydrobiopteridin (BH2) to tetrahydrobiopteridin (BH4) in a NADH-mediated reaction. BH4 is an essential molecule in the synthesis of serotonin and catecholaminergic neurotransmitters. As demonstrated by Masiello et al. (30), in the brain of streptozotocin-induced diabetic rats, its deficiency potentially results from reduced neurotransmitter synthesis in islets. Glutathione S-transferase was reduced 4-fold in lep/lep mice, as it was also in white adipose tissue.2 Glutathione S-transferase has also been found to be reduced in liver of lep/lep mice, and streptozoto-

---

2 J.-C. Sanchez, V. Converset, A. Nolan, G. Schmid, S. Wang, M. Heller, M. V. Sennit, D. F. Hochstrasser, and M. A. Cawthorne, unpublished results.
cin-induced diabetic rats (31), and in the placenta of overt
diabetic patients (32). Reactive intermediates generated
through metabolism are detoxicated by several systems. One
mechanism is the conjugation of biologically active electrophiles
with endogenous tripeptide glutathiones leading to the
final formation and excretion of mercapturic acid. The reaction
is catalyzed by glutathione \( S \)-transferase (33). The reasons for
this change in expression in islets are not known, but it could
result in decreased ability to undertake some detoxification
reactions.

Chromogranin A is a member of the granin family of acidic
secretory glycoproteins that are expressed in endocrine and
neuroendocrine cells. Chromogranin A is cleaved to several
peptides including chromostatin, pancreastatin, and parasta-
tin. They act mainly to inhibit hormone and neurotransmitter
release in an autocrine or paracrine manner (34). Proteolytic
cleavage of chromogranin A gives also rise to \( \beta \)-granin. This
N-terminal polypeptide product, which has no known func-
tion, was expressed 4-fold lower in islets of lep/lep mice than
in islets from controls. Calgranulin B, which is a member of the
S100 family of calcium-binding proteins (35), was 3-fold lower
in lep/lep islets. This could be involved in the abnormal \( \mathrm{Ca}^{2+} \)
signaling in islet cells and affects tyrosine-specific kinases
and the organization of the \( \beta \)-cell cytoskeleton.

Of the differentially expressed proteins modulated by ros-
glitazone, the adipocyte form of fatty acid-binding proteins
was 3-fold higher in islets from lep/lep mice than in their lean
counterparts. Fatty acid-binding proteins are present in a
number of tissues. Fatty acids are known to have a profound
effect on insulin secretion from islets. Thus acutely fatty acids
augment glucose-induced insulin secretion (36), whereas
chronic exposure to fatty acids results in an attenuation of
glucose-induced insulin secretion (37). The accumulation of
fatty acids in islets of Zucker diabetic fatty rats has been
associated with deterioration in islet cell responsiveness (38).
In the present study, rosiglitazone treatment lowered the ex-
pression level in the lep/lep mice to the level in controls.
Rosiglitazone is known to have significant effects on fatty acid
metabolism, and reduction in circulating non-esterified fatty
acids is an early event. Thus rosiglitazone treatment reduces
the exposure of islet cells to fatty acids, and hence the change
in binding protein may merely reflect changes in fatty acid
exposure. Tropomyosin is an actin-binding protein regulating
calcium-dependent cell contraction (39), whereas profilin af-

**Fig. 4.** Bar charts representing the relative spot volume detected by a differential expression analysis. Four differentially expressed proteins (tropomyosin isoform 1, adipocyte fatty acid-binding protein, profilin, and profilin fragment) were modulated in obese models \( n = 4 \) to the level in lean control \( n = 4 \) after rosiglitazone treatment \( p < 0.05 \).
ffects actin polymerization (40). Tropomyosin isoform 1 was underexpressed 4-fold, whereas profilin (and a fragment) were overexpressed 4-fold in \textit{lep/lep} mice relative to lean mice, and the expression pattern was normalized by rosiglitazone treatment. Interestingly, C57Bl/KsJ mice showed similar changes in differential expression to the \textit{lep/lep} mice.
suggesting that these changes in expression may be important to normal islet cell function. Changes in the actin cytoskeleton network occur during insulin granule secretion, and these changes are regulated by actin-binding proteins. However, the precise roles of tropomyosin and profilin in this process are not clear and neither is the mechanism of how rosiglitazone modulates the expression level.

A common feature of type 2 diabetes is an increased rate of secretion of proinsulin relative to insulin. Thus, in normal subjects proinsulin accounts for 2 to 4% of the total amount of secreted insulin, and it can reach up to 15% in type 2 diabetics (41). Recently it has been shown that, as well as producing evidence of islet cell protection, rosiglitazone treatment of type 2 diabetics reduces the proinsulin output (42). The processing of proinsulin has normally been associated with the activity of carboxypeptidase E (EC 3.4.17.10) (43, 44). This view has been challenged by the finding that mice with the fat mutation, a point mutation resulting in S202P and the production of an inactive enzyme that is not secreted, are still capable of producing insulin, albeit at lower levels (45). Fricker et al. (46) have provided evidence that carboxypeptidases are present in the secretory pathway and contribute to peptide processing. Carboxypeptidase B has the same enzymatic properties as carboxypeptidase E, but it is normally thought to be associated with exocrine secretion. However, the carboxypeptidase B precursor sequence has been found in an adult mouse islet of Langerhans library. This is consistent with the current finding that carboxypeptidase B precursor protein is found in mouse islets. The 5-fold increase in expression induced by rosiglitazone treatment of both normal and lep/lep mice suggests that rosiglitazone may have a primary action to increase proinsulin to insulin conversion through an increase in expression of carboxypeptidase B precursor protein.

In conclusion, the array of mouse pancreatic islets by two-dimensional gel electrophoresis and further identification of differentially expressed proteins by mass spectrometric analysis provided evidence that modulation of actin-binding protein expression by BRL49653 may be an important aspect of its protective effect on islet cell structure and function. In addition, rosiglitazone increased carboxypeptidase B precursor protein expression in both lep/lep and normal mice suggesting that this might be an independent effect of rosiglitazone that contributes to improved insulin processing.

Acknowledgments — We thank G. Boehm and G. Rossellat for technical assistance.

* This work was supported by Proteome Sciences plc (Cobham, Surrey, United Kingdom). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Geneva Proteomics Center, Central Clinical Chemistry Laboratory, Geneva University Hospital, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland. Tel.: 41-22-372-73-74; Fax: 41-22-372-73-99; E-mail: sanchez@dim.hcuge.ch.

REFERENCES

1. Zimmet, P., Alberti, K. G., and Shaw, J. (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782–787

2. Elbein, S. C. (1997) The genetics of human non-insulin-dependent (type 2) diabetes mellitus. J. Nutr. 127, 1891S–1896S

3. Tautz, D. (1992) Redundancies, development and the flow of information. Bioessays 14, 263–266

4. Gerich, J. E. (2002) Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 51, Suppl. 1, 117–121

5. Scheen, A. J., and Lefebvre, P. J. (1999) Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Saf. 12, 32–45

6. Bernard-Kargar, C., and Ktorza, A. (2001) Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 50, Suppl. 1, 30–35

7. Claraldi, T., and Henry, R. R. (1997) Thiazolidinediones and their effects on glucose transporters. Eur. J. Endocrinol. 137, 610–612

8. Buckingham, R. E., Al-Barazanji, K. A., Toseland, C. D., Slaughter, M., Connor, S. C., West, A., Bond, B., Turner, N. C., and Clapham, J. P. (1998) Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47, 1326–1334

9. Jones, N. P., Charbonnel, B., Lannqvist, F., Owen, S., and Patwardhan, R., (1999) Rosiglitazone reduces plasma insulin and its precursor while decreasing glycaemia in type 2 diabetes. Diabetologia 42, Suppl. 1, 859 (Abstr. 22)

10. Swenne, I., and Andersson, A. (1984) Effect of genetic background on the capacity for islet cell replication in mice. Diabetologia 27, 464–467

11. Korsgren, O., Jansson, L., Sandler, S., and Andersson, A. (1990) Hyperglycaemia-induced B cell toxicity. The fate of pancreatic islets transplanted into diabetic mice is dependent on their genetic background. J. Clin. Invest. 86, 2161–2168

12. Kaku, K., Province, M., and Permutt, M. A. (1989) Genetic analysis of obesity-induced diabetes associated with a limited capacity to synthesize insulin in C57BL/KS mice: evidence for polygenic control. Diabetologia 32, 636–643

13. Hochstrasser, D. F., Frutiger, S., Paquet, N., Bairoch, A., Ravier, F., Pasquali, C., Sanchez, J. C., Tissot, J. D., Bjellqvist, B., Vargas, R., and Appel, R. D. (1992) Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis 13, 992–1001

14. Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E. Z., Alhauud, G., Young, P., Watmore, M. A., and Grimaldi, P. A. (1994) Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46, 1070–1076

15. Pallett, A. L., Morton, N. M., Watmore, M. A., and Eminsson, V. (1997) Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem. Biophys. Res. Commun. 238, 267–270

16. Bjellqvist, B., Pasquali, C., Ravier, F., Sanchez, J. C., and Hochstrasser, D. F. (1993) A nonlinear wide-range immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14, 1357–1365

17. Garg, A., Postel, W., Gunther, S., Weser, J., Strahler, J. R., Hanash, S. M., Somerfeld, L., and Kuick, R. (1998) Approach to stationary two-dimensional pattern: influence of focusing time and immobiline/carrier amphotelyte concentrations. Electrophoresis 9, 37–46

18. Hochstrasser, D. F., Harrington, M. G., Hochstrasser, A. C., Miller, M. J., and Merrill, C. R. (1988) Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal. Biochem. 173, 424–435

19. Hochstrasser, D. F., and Merrill, C. R. (1988) “Catalysts” for polycrylamide gel polymerization and detection of proteins by silver staining. Appl. Theor. Electrophor. 1, 35–40

20. Hochstrasser, D. F., Patchornik, A., and Merrill, C. R. (1988) Development of polycrylamide gels that improve the separation of proteins and their detection by silver staining. Anal. Biochem. 173, 412–423

21. Oakley, B. R., Kirsch, D. R., and Morris, N. R. (1980) A simplified ultrasen-
Anne, D., Palagi, P. M., Walther, D., Vargas, J. R., Sanchez, J. C., Ravier, F., Pasquale, C., and Hochstrasser, D. F. (1997) Melanie II—a third-generation software package for analysis of two-dimensional electrophoresis images: I. Features and user interface. Electrophoresis 18, 2724–2734

Duhault, J., Boulanger, M., Espinal, J., Marquie, G., Petkov, P., and du Boisfusseul, R. (1995) Latent autoimmune diabetes mellitus in adult humans with non-insulin-dependent diabetes: is Psammomys obesus a suitable animal model? Acta Diabetol. 32, 92–94

Sanchez, J.-Ch., Chiappe, D., Converset, V., Hoogland, C., Binz, P.-A., Paesano, S., Appel, R. D., Wang, S., Sennitt, M., Nolan, A., Cavthorne, M. A., and Hochstrasser D. F. (2001) The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics 1, 136–163

Tomita, T., Douil, V., Pollock, H. G., and Krizsan, D. (1992) Pancreatic islets of obese hyperglycemic mice (ob/ob). Pancr. 7, 367–375

Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. M., (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432

Stephens, T. W., Basinski, M., Bristow, P. K., Bue-Valeskey, J. M., Burgett, S. G., Caff, L., Hale, J., Hoffmann, J., Hsiung, H. M., and Kriauciunas, A. (1995) The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377, 530–532

Caro, J. F., Sinha, M. K., Kolaczynski, J. W., Zhang, P. L., and Considine, R. V. (1998) Leptin: the tale of an obesity gene. Diabetes 45, 1455–1462

Wang, M. Y., Koyama, K., Shimabukuro, M., Newgard, C. B., and Unger, R. H. (1998) OB-Rb gene transfer to leptin-resistant islets reverses diabetes-associated weight protein in non-muscle cells. Proc. Natl. Acad. Sci. U. S. A. 95, 714–718

Masiello, P., Balesteri, E., Baccioni, D., and Bergamini, E. (1987) Influence of experimental diabetes on brain levels of monoamine neurotransmitters and their precursor amino acids during tryptophan loading. Acta Diabetol. Lat. 24, 43–50

Barnett, C. R., Abbott, R. A., Bailey, C. J., Flatt, P. R., and Ioannides, C. (1992) Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes. Bioch. Pharmacol. 43, 1868–1871

Glover, D. D., McRobie, D. J., and Tracy, T. S. (1998) Effects of gestational and overt diabetes on placental cytochromes P450 and glutathione S-transferase. Prim. Care Update Ob. Gyns. 5, 189

Habig, W. H., Pabst, M. J., and Jakoby, W. B. (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249, 7130–7139

Iacangelo, A., Affolter, H. U., Eiden, L. E., Herbert, E., and Grimes, M. (1986) Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. Nature 323, 82–86

Donato, R. (1999) Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim. Biophys. Acta 1450, 191–231

Konrad, R. J., Stoller, J. Z., Gao, Z. Y., and Wolf B. A. (1998) Eicosapentaenoic acid (C20:5) augments glucose-induced insulin secretion from beta-T3 insulinoma cells. Pancr. 13, 253–258

Ritz-Laser, B., Meda, P., Constant, I., Klages, N., Charollais, A., Morales, A., Magnan, C., Ktorza, A., and Philippe, J. (1999) Glucose-induced preproinsulin gene expression is inhibited by the free fatty acid palmitate. Endocrinology 140, 4005–4014

Lee, Y., Hirose, H., Ohneda, M., Johnson, J. H., McGarry, J. D., and Unger, R. H. (1994) Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. U. S. A. 91, 10878–10882

Vincent, D., Piper, M., Gammeltoft, S., Maratos-Flier, E., and Kahn, C. R. (1998) Alterations in skeletal muscle gene expression of ob/ob mice by mRNA differential display. Diabetes 47, 1451–1458

Carlsson, L., Nystron, L. E., Sundkvist, I., Markey, F., and Lindberg, U. (1997) Actin polymerizability is influenced by profilin, a low molecular weight protein in non-muscle cells. J. Mol. Biol. 115, 485–483

Ward, W. K., LaCava, E. C., Paquette, T. L., Beard, J. C., Wallum, B. J., and Porte, D. (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30, 698–702

Werner, A. L., and Travaglini, M. T. (2001) A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21, 1082–1099

Fricker, L. D. (1986) Carboxypeptidase E. Annu. Rev. Physiol. 50, 309–321

Fricker, L. D. (1991) in Peptide Biosynthesis and Processing (Fricker, L. D., ed) pp. 190–230, CRC Press, Boca Raton, FL

Naggert, J. K., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steinier, D. F., Carroll, R. J., Paigen, B. J., and Leiter, E. H. (1995) Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat. Genet. 10, 135–142

Fricker, L. D., Berman, Y. L., Leiter, E. H., and Devi, L. A. (1996) Carboxypeptidase E activity is deficient in mice with the fat mutation. Effect on peptide processing. J. Biol. Chem. 271, 30619–30624